Detail akcie Cumberland Ph online

Business Summary: Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Cumberland Pharmaceuticals, Inc. revenues decreased 6% to $39.6M. Net loss increased 13% to $6.3M. Revenues reflect Sancuso segment decrease of 39% to $8.1M, Caldolor segment decrease of 10% to $4.3M. Higher net loss reflects Selling and Marketing - Balancing value increase of 14% to $14.7M (expense), General and Administrative - Balanc increase of 6% to $10.5M (expense).